BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma

The introduction of immune checkpoint blockade (ICB) and BRAF-MEK inhibitors has substantially improved outcomes in patients with metastatic melanoma. However, several challenging factors may hinder the efficacy of ICB in patients with symptomatic intracranial metastatic melanoma who are immunosuppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaddour, Karam, Johanns, Tanner M, Ansstas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162174/
https://www.ncbi.nlm.nih.gov/pubmed/34084449
http://dx.doi.org/10.2217/mmt-2020-0022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162174/
https://www.ncbi.nlm.nih.gov/pubmed/34084449
http://dx.doi.org/10.2217/mmt-2020-0022

Ejemplares similares